&nbsp;

Aug 2023

Drug

IDArubicin

Other Name(s): Idamycin®

Quick Link(s):

Oct 2023

Drug

arsenic trioxide

Other Name(s): Trisenox®

Quick Link(s):

Oct 2023

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Feb 2023

Regimen

AZCT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML),

Myelodysplastic Syndrome (MDS),

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts

Drugs Used:

azaCITIDine

Quick Link(s):

Regimen Monograph

Jul 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

ALEM+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

alemtuzumab (Compassionate),

riTUXimab (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

IDEL+RITU; IDEL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria

New Drug Funding Program

Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

idelalisib,

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Drugs Used:

iBRUtinib (Unfunded)

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

IRINRALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

irinotecan,

raltitrexed

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

INOT

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Inotuzumab Ozogamicin (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia

Drugs Used:

inotuzumab ozogamicin